FDA Approval Received On Covalon Technologies Inc.'s New Collagran’TM’ And Collagran Ag’TM’ Advanced Wound Dressings With Matrix Metalloprotease ‘MMP’ Inhibiting Activity

Covalon Technologies Ltd. ("Covalon") (TSX VENTURE:COV) announces that the FDA has approved Covalon's proprietary CollagranTM and Collagran Ag™ new collagen-based wound dressings for use in the USA.